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Abstract
Hypopituitarism is common after moderate and severe traumatic brain injury (TBI). Herein, we address the association
between mild TBI (mTBI) and pituitary and metabolic function in retired football players. Retirees 30–65 years of age,
with one or more years of National Football League (NFL) play and poor quality of life (QoL) based on Short Form 36
(SF-36) Mental Component Score (MCS) were prospectively enrolled. Pituitary hormonal and metabolic syndrome
(MetS) testing was performed. Using a glucagon stimulation test, growth hormone deficiency (GHD) was defined with a
standard cut point of 3 ng/mL and with a more stringent body mass index (BMI)-adjusted cut point. Subjects with and
without hormonal deficiency (HD) were compared in terms of QoL, International Index of Erectile Function (IIEF) scores,
metabolic parameters, and football career data. Of 74 subjects, 6 were excluded because of significant non-football-related
TBIs. Of the remaining 68 subjects (mean age, 47.3 – 10.2 years; median NFL years, 5; median NFL concussions, 3; mean
BMI, 33.8 – 6.0), 28 (41.2%) were GHD using a peak GH cutoff of < 3 ng/mL. However, with a BMI-adjusted definition
of GHD, 13 of 68 (19.1%) were GHD. Using this BMI-adjusted definition, overall HD was found in 16 (23.5%) subjects:
10 (14.7%) with isolated GHD; 3 (4.4%) with isolated hypogonadism; and 3 (4.4%) with both GHD and hypogonadism.
Subjects with HD had lower mean scores on the IIEF survey ( p = 0.016) and trended toward lower scores on the SF-36
MCS ( p = 0.113). MetS was present in 50% of subjects, including 5 of 6 (83%) with hypogonadism, and 29 of 62 (46.8%)
without hypogonadism ( p = 0.087). Age, BMI, median years in NFL, games played, number of concussions, and ac-
knowledged use of performance-enhancing steroids were similar between HD and non-HD groups. In summary, in this
cohort of retired NFL players with poor QoL, 23.5% had HD, including 19% with GHD (using a BMI-adjusted definition),
9% with hypogonadism, and 50% had MetS. Although the cause of HD is unclear, these results suggest that GHD and
hypogonadism may contribute to poor QoL, erectile dysfunction, and MetS in this population. Further study of pituitary
function is warranted in athletes sustaining repetitive mTBI.
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Introduction
Concussion is a well-known hazard of all contact sports. Itis estimated that between 1.6 and 3.8 million sports-related
traumatic brain injuries (TBIs) occur yearly in the United States.1,2
Recurrent concussion in the National Football League (NFL) is
common. Despite the increased sophistication of helmets and rules
to minimize the risk of concussions, mild TBI (mTBI) remains
relatively common.3 Of 1200 NFL concussions that were reported
between 1996 and 2007, 29% of players sustained at least 2 or more
concussions.4 More recently, from NFL Injury Surveillance data
over the last 4 years ending in 2012, with 256 games per season,
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there was an average of 170 concussions annually (or 0.66 con-
cussions per game; NFL Injury Surveillance). Recurrent concus-
sion in the NFL has been associated with development of
depression, cognitive impairment, and poor quality of life (QoL) in
retirees.5,6
Another potential sequelae of repetitive mTBI is pituitary hor-
monal dysfunction which is known to occur in 20–40% of moderate
and severe TBI (sTBI) patients.7–18 Prospective cohort studies
published since 2000 in moderate and sTBI patients show that
growth hormone (GH) and gonadotropin deficiencies are the most
common endocrinopathies, whereas hypothyroidism, adrenal in-
sufficiency, and diabetes insipidus are less common.7–18 To date,
there have been no prospective studies addressing the possible
relationship between football-related concussion and long-term
hypopituitarism. However, a recent case report in an adolescent
football player with multiple concussions and anterior hypopitu-
itarism has highlighted this association.19 Studies in kickboxers and
retired boxers also have reported relatively high rates of hypopi-
tuitarism; in one report, isolated GH deficiency (GHD) was docu-
mented in 45% of subjects, and the severity of GHD correlated with
the number of bouts and boxing career duration.20–23 In another
study by Bondanelli and colleagues, chronic hypopituitarism was
observed in 37% of mTBI patients.10
Given the high rate of repetitive head impact and recurrent
concussion in professional football players, and the depression,
poor QoL, and obesity that are relatively common among NFL
retirees, we hypothesized that pituitary dysfunction could be a
contributing factor to their poor physical and mental health status.
To address these issues, a prospective study of retired NFL players
with relatively low QoL scores was designed. Specifically, we
sought to 1) determine the rate of pituitary hormonal dysfunction,
sexual dysfunction, and associated metabolic dysfunction in these
retirees, 2) compare degrees of poor QoL as well as sexual and
metabolic dysfunction in retirees with and without hormonal dys-
function, and 3) determine which, if any, factors of the retirees’
football career, including number of concussions sustained, number
of years played, games played, and positions played, were associ-
ated with hormonal dysfunction.
Methods
Initial screening, eligibility, and exclusion criteria
Subjects were recruited from a database developed over 9 years
at the Center for the Study of Retired Athletes (CSRA) in collab-
oration with the National Football League Players’ Association.
From this database of over 2800 retirees, 430 retired NFL players
were identified who meet the following criteria: 1) age 30–65 who
played at least 1 year in the NFL; 2) completed the CSRA Health
Survey of Retired NFL Players questionnaire5,6,24 the Short Form
36 (SF-36) quality-of-life assessment and the International Index of
Erectile Function (IIEF) survey; and 3) had poor QoL based on an
SF-36 Mental Component Score (MCS) of < 49 (Fig. 1). Although
an MCS of 49 represents the 25th percentile and below which
corresponds to a significantly impaired QoL in U.S. men, the cri-
teria was relaxed near the end of the study to an MCS of < 53,
which is the median for adult men, to allow completion of enroll-
ment.16,17 These 430 players were contacted by mail inviting them
to participate in this study. If agreeable, they were asked to provide
a medication list and complete a questionnaire regarding prior
history of treatment for any pituitary hormonal disorders and prior
hormone and steroid use, including performance-enhancing ste-
roids during their NFL career. Study exclusion criteria included
terminal illness (e.g., advanced cancer or acquired immune defi-
ciency syndrome), recent glucocorticoid use (within the last 3
months), diagnosis of pituitary insufficiency made before NFL
retirement, and history of pituitary surgery or irradiation.
The CSRA Health Survey of Retired NFL Players questionnaire,
which has been utilized in many previous reports of retired NFL
players, asked for a detailed concussion history, including con-
cussions sustained in high school, collegiate, and professional
football.5,6,24 A concussion was clearly defined for study partici-
pants as follows: ‘‘a concussion is a blow to the head followed by a
variety of symptoms that may include any of the following: head-
ache, dizziness, loss of balance, blurred vision, ‘seeing stars’,
FIG. 1. Flow diagram for subject recruitment, eligibility, and enrollment. QOL, quality of life; IIEF, the International Index of
Erectile Function.
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feeling in a fog or slowed down, memory problems, poor concen-
tration, nausea, or throwing-up. Getting ‘knocked out’ or being
unconscious does NOT always occur with a concussion.’’ In ad-
dition to the number of concussions sustained, the survey asked
about how many times a physician or athletic trainer evaluated
them after a concussion, how many times there was a loss of con-
sciousness (LOC) and/or memory loss, and how often they returned
to play immediately after a concussion. Using the same concussion
definition, Guskiewicz and colleagues observed high reliability in
the self-reporting of earlier concussions (*25 years earlier) when
surveyed 18–24 months apart among former NFL players.5 Kerr
and colleagues observed moderate reliability in the self-reporting
of a similar cohort of former NFL players when surveyed 9 years
apart.25
Testing of enrolled subjects
Consented subjects were tested at Saint John’s Health Center,
Santa Monica, or Los Angeles Biomedical Research Institute
(LABioMed) at Harbor-UCLA Medical Center (Torrance, CA),
beginning with hormonal and metabolic function testing in the
morning followed by a brief interview addressing TBI history in
and outside their NFL career, as well as other relevant demographic
information (e.g., education level), completion of structured
questionnaires, and psychological and neuropsychological testing
in the afternoon. We report on QoL and erectile function data
from this assessment; additional data from the assessment will be
reported in other articles.
Pituitary hormonal testing
After an overnight fast, all participants were admitted to the
testing center at 7 am to obtain weight, height, and vital signs and
for an intravenous (i.v.) catheter insertion. Testing began at 8 am
with baseline blood draws at - 30 min and time zero. These initial
blood draws included 1) luteinizing hormone (LH), follicle-
stimulating hormone (FSH), and free and total testosterone to assess
gonadal function, 2) free T4, total T4, and thyroid-stimulating hor-
mone (TSH) to assess thyroid function, 3) prolactin level to assess for
lactotroph dysfunction, and 4) serum and urine sodium and osmo-
lality and urine specific gravity were also collected to assess posterior
pituitary function. Testing for GHD and adrenal insufficiency were
assessed sequentially using stimulation tests. For GHD, at time zero,
an insulin-like growth factor 1 (IGF-1) level was drawn, then a
glucagon (1 mg; 1.5 mg, if > 90 kg) i.v. push was given to assess for
GHD with serial measurements of GH at 90, 120, 150, and 180 min.
For adrenal insufficiency, adrenocorticotrophic hormone (ACTH)
and cortisol levels were drawn at time zero, then a Cortrosyn
250 lg i.v. push was administered at time 180 min with serial mea-
surements of cortisol at 210 and 240 min after baseline.
Serum and urine samples for all subjects were stored at - 20C
before assay and then measured in the Endocrine and Metabolic
Research Laboratory at LABioMed using previously published
validated methods.26,27
As detailed in Table 1, pituitary hormonal deficiencies were
defined as follows: corticotroph axis: peak cortisol levels after
Cortrosyn below the 5th percentile (< 12.0 lg/dL); thyrotroph axis:
total T4 levels below the 5th percentile (< 4.9 lg/dL); and gona-
dotroph axis: total testosterone levels below the 5th percentile
(< 265 ng/mL). Prolactin levels either above or below the reference
range were noted (3–15.4 ng/mL). Criteria for GHD using a control
cohort is described below.
Control cohort for defining growth hormone deficiency
and adjusting for body mass index
Whereas weight per se has not been shown to be a factor in GH
responsiveness, central obesity has been well documented to reduce
24-h endogenous GH secretion and lower peak GH levels in re-
sponse to GH stimulation testing.28–30 Consequently, BMI-adjusted
cut points for GH stimulation testing test have been proposed and
are currently recommended by several consensus guidelines.31,32
Because of this known inverse relationship with BMI and peak GH
after stimulation testing with glucagon, GHRH/arginine, and in-
sulin tolerance testing, GHD was defined at 3 cut points, adjusted
for BMI using a normal non-head-injured control cohort referred to
the Dynamic Endocrine Testing Unit at the Oregon Health & Sci-
ence University (Portland, OR) for assessment of possible GHD
with low normal to low serum IGF-1 levels.27,33–36 From 119 men
tested, individuals were excluded if they had a previous history of
pituitary or hypothalamic tumor, other hypothalamic or pituitary
disorder, pituitary surgery or irradiation, or TBI. Thirty individuals
from these 119 men met the criteria and made up the control group.
Of these 30 control subjects, 7 had primary hypothyroidism, 5 had
primary hypogonadism, and 1 had secondary ACTH deficiency
from previous glucocorticoid exposure for Crohn’s colitis. All
subjects at the time of glucagon stimulation testing were on
adequate replacement of thyroid, testosterone, and glucocorti-
coid hormones. In this cohort, a strong inverse correlation was
found between BMI and peak GH. A reference range for BMI < 30
and BMI ‡ 30 used the 5th percentile as the cutoff for defining
GHD. From this analysis, the cut points for defining GHD by
peak GH after glucagon stimulation testing are: BMI < 25 kg/m2:
< 3 ng/mL; BMI 25–30 kg/m2: < 0.9 ng/mL; and BMI > 30 kg/m2:
< 0.5 ng/mL. The Results section shows the overall HD rates using
the standard cut point of 3 ng/mL for defining GHD as well as
with a more stringent BMI-adjusted cut point for defining
GHD. However, for all comparisons of the HD versus non-HD
cohorts, the more stringent BMI-adjusted cut point for defining
GHD was used.
Criteria for the presence of central diabetes insipidus were urine
specific gravity £ 1.005, urine osmolality < 500 mOsm/kg, and
serum sodium > 140 mmol/L in the setting of frequent urination (at
least two times per night and excessive/chronic thirst).
Metabolic syndrome definition
Fasting glucose, insulin, and lipid panel were calculated by the
homeostatic model assessment for insulin resistance and urine
microalbumin. Insulin assays were performed at the Endocrine and
Metabolic Research Laboratory. MetS was considered present
when three or more of the following seven parameters met the
following thresholds: fasting glucose > 110 mg/dL; high-density
lipoprotein cholesterol < 40 mg/dL, triglycerides > 150 mg/dL or
on treatment for hyperlipidemia; systolic blood pressure > 130 mm
Hg; diastolic blood pressure > 85 mm Hg; or on antihypertensive
medication; and waist circumference > 102 cm.37
Table 1. Anterior Pituitary Hormonal Testing Battery
Axis Test Normal range
Thyroid TSH, total T4 total T4: 4.9–11.7 lg/dL
Adrenal Cortrosyn stimulation peak cortisol:
12.0–25.7 lg/dL
Gonadal LH, FSH, total
testosterone
total T: 265–973 ng/dL
GH Glucagon stimulation peak GH:
BMI < 25: ‡ 3 ng/mL
BMI 25–30: ‡ 0.9 ng/mL
BMI > 30: ‡ 0.5 ng/mL
Lactotroph Prolactin prolactin 3.0–15.4 ng/mL
TSH, thyroid-stimulating hormone; LH, luteinizing hormone; FSH,
follicle-stimulating hormone; BMI, body mass index; GH, growth
hormone.
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Demographic and NFL play information
Demographic data included age, education level, number of
seasons and games played, positions played, number of concus-
sions sustained during professional football, collegiate, and high
school play (obtained from the CSRA Health Survey of Retired
NFL Players questionnaire), as well as non-sports-related TBIs. If,
on detailed questioning, subjects had sustained a significant TBI
outside their football career (defined as an LOC of 30 min or
greater), they were excluded.
Quality of life and erectile function
The SF-36 data and IIEF survey, well-established widely vali-
dated self-assessment tools, were utilized in the current study.
Subjects were considered to have erectile dysfunction if their IIEF
score was < 25 (score range, 5–75).16,17,38,39 Subdomain analysis
was also performed for IIEF: erectile function (questions 1 through
5 and 15; possible total score, 1–30); orgasmic function (questions
9 and 10; possible total score, 0–10); sexual desire (questions 11
and 12; possible total score, 2–10); intercourse satisfaction (ques-
tions 6, 7, and 8; possible total score, 0–15); and overall satisfaction
(questions 13 and 14; possible total score, 2–10).39
Approval
The institutional review boards of each participating center ap-
proved this study, and all participants voluntarily consented to
study participation by signing an informed consent form.
Statistical analysis
Hypopituitarism, metabolic syndrome, and body mass
index. Subjects were considered hormonally deficient (HD) for a
given axis if their values were below the normal range, as defined in
Table 1. Deficiency rates for the cohort for each hormonal axis were
calculated. Mean values for the HD and non-HD groups were
calculated for each hormonal axis. Rates of MetS (chi-square test)
and mean BMI (Student’s t-test) were compared between the HD
and non-HD subjects. The change in BMI over time since retire-
ment was also examined and compared between the HD and non-
HD subjects using mixed model with random effect (subjects) and
fixed effects (HD group and years since retirement).
Differences in quality of life and erectile function. Results
from SF-36 and IIEF survey were compared in the HD and non-HD
using the Student’s t-test (for continuous variables) and the chi-
square test (for categorical variables).
Risk factor assessment for hormonal deficiency. The
number of self-reported concussions in NFL and non-NFL football
seasons (including collegiate and high school), number of profes-
sional football games played, years in the NFL and other profes-
sional football leagues, as well as age and position played were
compared in the HD and non-HD groups using the Student’s t-test
(for continuous variables) or chi-square test (for categorical vari-
ables). Position played was compared between the two groups us-
ing the chi-square test. The primary position played was also
assessed by comparing high-frequency impact (offensive line, de-
fensive line, linebacker, and special teams) versus low-frequency
impact positions.40 p values < 0.05 were deemed statistically sig-
nificant. Data are represented as mean – standard deviation (SD).
Results
In total, 74 of 430 (17%) invited professional football retirees
were studied. On detailed questioning, 6 subjects had sustained
significant non-sports-related TBIs outside of their football careers
and were excluded from analysis. None of the 6 excluded subjects
had hypopituitarism based on hormonal testing. Demographic,
hormonal, metabolic, and QoL testing results are presented on the
remaining 68 subjects. As shown in Table 2, the 68 subjects ranged
in age from 30 to 65 years, with a median number of years in the
NFL of 5 (range, 1–17); 62 of 68 (91.2%) had an SF-36 MCS of
£ 49. Only 3 (4.4%) subjects reported having sustained no con-
cussions, and 37 (54.4%) reported having 3 or more NFL career
concussions.
Pituitary hormonal dysfunction, metabolic syndrome
and body mass index
Using a standard peak GH cutoff of < 3 ng/mL to define GHD,
28 of 68 (41.2%) subjects were GH deficient, however, using a
more stringent BMI-adjusted definition of GHD, 13 of 68 (19.1%)
were GH deficient. Using this more stringent definition for GHD,
overall, HD was found in 16 (23.5%) of 68 subjects, including 10
(14.7%) with isolated GHD, 3 (4.4%) with isolated hypogonadism,
and 3 (4.4%) with both GHD and hypogonadism. In total, GHD was
found in 13 (19.1%) using the BMI-adjusted definition and hypo-
gonadism in 8.8% (Table 2). Of the 6 subjects with hypogonadism,
all had normal or low gonadotropins (LH and FSH), indicating a
pituitary/hypothalamic origin. No patients had hypothyroidism
adrenal insufficiency, hyperprolactinemia, or diabetes insipidus.
Comparing the HD versus the non-HD subjects (using the BMI-
adjusted definition for GHD), mean IGF-1 levels, IGF-1 z-scores
(adjusted for age), and total testosterone levels were significantly
lower in the HD subjects, but all other mean hormonal levels, in-
cluding those of total T4, free T4, peak cortisol, and prolactin, were
similar between the two groups (Table 3).
Using the BMI-adjusted definition of GHD, MetS was present in
34 (50.0%) subjects, including 9 (56.3%) and 25 (48.1%) of HD and
non-HD subjects, respectively, ( p = 0.568). Categorized by hor-
monal deficiency, MetS was present in all subjects with both GHD
Table 2. Demographics, Hormonal Deficiency
and Metabolic Syndrome in 69 NFL Retirees
Variable
Mean – SD or
median (range)
Age 47.3 – 10.2 (30–65)
BMI 33.8 – 6.0 (24–51)
Years since retirement 18.5 (2–41)
Years in NFL 5 (1–17)
NFL games played 54 (0–241)
Frequency (%)
GH deficiencya 13 (19.1)
Testosterone deficiency 6 (8.8)
GH and testosterone deficiency 3 (4.4)
Any hormonal deficiency 16 (23.5)
Metabolic syndrome 34 (50.0)
BMI > 30 45 (66.2)
High-frequency impact positionb 44 (64.7)
aIf GH deficiency criteria had not been adjusted for BMI, and the
standard cutoff of peak GH < 3 ng/mL had been used, 28 of 68 (41.2%)
subjects would have been classified as GH deficient. No subjects had
hypothyroidism, adrenal insufficiency, or diabetes insipidus.
bGuskiewicz and colleagues.33
NFL, National Football League; BMI, body mass index; GH, growth
hormone; SD, standard deviation.
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and hypogonadism (n = 3), 66.7% of subjects with isolated hypo-
gonadism (n = 3), 40% with isolated GHD (n = 10), and 48.1% in
those with no hormonal deficiency (n = 52). Compared to the 62
subjects without hypogonadism, the 6 subjects with hypogonadism
had a higher rate of MetS (83.3% vs. 46.8%; p = 0.087) and higher
BMI (36.0 – 6.6 vs. 33.6 – 5.9; p = 0.338), but these differences
were not statistically significant.
BMI at time of testing was inversely correlated with peak GH
after glucagon stimulation testing, as shown in Figure 2. However,
BMI was similar between the HD and non-HD groups (34.0 – 6.2
vs. 33.7 – 6.0; p = 0.853). The percent of obese subjects (BMI > 30)
at the time of testing was also similar (56.3% for HD and 69.2% for
non-HD subjects). Based on subjects’ reported weight at retire-
ment, BMI increased significantly for the cohort overall from time
of retirement to time of testing ( p = 0.001), but the change in BMI
over time was similar between the HD and non-HD groups ( p value
from linear mixed model = 0.214; Fig. 3).
Quality of life and erectile function
Comparing the HD and non-HD groups (using the BMI-adjusted
definition for GHD), there was a trend toward lower mean SF-36
MCS (32.9 – 10.5 vs. 37.4 – 9.6, respectively; p = 0.113), although
SF-36 PCS scores were similar (44.1 – 13.4 vs. 43.0 – 10.5, re-
spectively; p = 0.740; Table 4). IIEF scores were lower in the HD
group (42.8 – 20.0 vs. 55.2 – 16.8; p = 0.016), but the rate of erectile
dysfunction (IIEF score < 25) in the HD and non-HD groups was
similar (18.8% vs. 9.8%; p = 0.336). Of 6 retirees with low testos-
terone, 3 (50%) had IIEF scores under 25, compared to 5 of 61
(8.2%) retirees with normal testosterone ( p = 0.003). Subdomain
analyses of IIEF (sexual desire, overall satisfaction, erectile func-
tion, orgasmic function, and intercourse satisfaction) showed no
significant differences between HD and non-HD groups. Retirees
with low testosterone levels had significantly lower erectile func-
tion (19.00 – 7.75 vs. 25.47 – 5.06; p = 0.021) and orgasmic func-
tion (6.75 – 2.87 vs. 8.79 – 1.75; p = 0.035) scores, compared to the
eugonadal group. Those who had MetS had lower IIEF score,
compared to those who did not have MetS (55.81 – 13.86 vs.
61.90 – 8.55; p = 0.057) and significantly lower erectile function
subdomain score (23.21 – 6.36 vs. 26.76 – 3.76; p = 0.014).
Risk factors for hormonal deficiency: demographics,
concussion history, and steroid use
As shown in Table 5, the HD and non-HD groups (using the
BMI-adjusted definition for GHD) were similar in terms of mean
age, median seasons in the NFL, games played, and number of
concussions sustained in both NFL and non-NFL leagues (includ-
ing high school and collegiate). The non-HD group had a higher
mean years of play in the NFL, compared to the HD group (6.1 – 4.0
vs. 3.9 – 2.8; p = 0.045). The distribution of high- versus low-
frequency impact positions was also similar between the two groups.
Regarding performance-enhancing steroid use, in total, 9 of 68
(13.2 %) subjects acknowledged steroid use, including 3 of 15 in
Table 3. Hormonal Test Results in Hormonally







(n = 16) p value
Peak GH after GST 6.9 – 5.7 1.0 – 1.9 < 0.0001
IGF-1 174.1 – 67.3 127.1 – 61.4 0.015
IGF-1 z-score, age 2.9 – 1.9 1.6 – 1.6 0.020
Total testosterone 486.2 – 129.9 340.9 – 115.1 0.0002
Prolactin 7.4 – 3.2 8.5 – 3.5 NS (0.243)
Total T4 7.0 – 1.5 7.6 – 1.3 NS (0.172)
Peak cortisol 28.2 – 3.6 29.1 – 6.6 NS (0.622)
Values are shown as mean – standard deviation.
GH, growth hormone; GST, glucagon stimulation test; IGF-1, insulin-
like growth factor 1; NS, not significant.
FIG. 2. Peak GH after glucagon stimulation as a function of BMI. The 13 subjects with GH deficiency denoted by diamonds; non-GH
deficient are denoted by squares. GH, growth hormone; BMI, body mass index.
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FIG. 3A. Changes in BMI since retirement to time of testing for all 58 subjects. Subjects with hormonal deficiency are shown by
dashed lines and subjects without hormonal deficiency with solid lines. BMI, body mass index.
FIG. 3B. Change in BMI since retirement to time of testing grouped for subjects with hormonal deficiency (dashed line) and without
hormonal deficiency (solid line). BMI, body mass index.
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the HD group (20%) and 6 of 52 (11.5%) in the non-HD group
( p = 0.4075; Fisher’s exact test); 1 subject in the HD group did not
answer the question on his survey. Of the 3 HD subjects who ac-
knowledged steroid use, duration was given as 1 year for each
subject and all subjects had been retired for at least 10 years at the
time of hormonal testing. In the 6 non-HD subjects, duration of
steroid use ranged from 1 month to 7 years.
Discussion
Summary of findings
The most important finding in this prospective study was that
pituitary dysfunction and MetS are relatively common in retired
professional football players and may be significant contributors to
their poor QoL. However, years played in the NFL and concussion
history were not associated with these hormonal and metabolic
dysfunctions. In this cohort of 68 NFL retirees with poor, QoL
based on SF-36 MCS, 23.5% had pituitary hormonal dysfunction,
including 19.1% with GHD, 8.8% with hypogonadism, and 4.4%
with both GHD and hypogonadism. In addition, MetS was present
in 50.0%. Notably, there was a relatively high rate of GHD, despite
using very stringent BMI-adjusted definitions of the glucagon
stimulation test to confirm the presence of GHD. The 6 subjects
with low testosterone had a high rate of sexual dysfunction
(50.0%), including decreased erectile and orgasmic function, MetS
(83.3%), and obesity (83.3%; BMI > 30). Including all 16 subjects
with either low testosterone and/or GH deficiency, there was a trend
toward lower QoL based on the SF-36 MCS. There were no clear
risk factors for hormonal deficiency related to concussion history or
position played, although 64.7% of retirees played positions with a
high frequency of head impact. The implications of these findings
are discussed below.
Defining hormonal deficiency
In this study, standard pituitary hormonal testing was used, in-
cluding stimulation testing for the corticotroph and somatotroph
axes.41 For GHD, we utilized the glucagon stimulation test, which is a
well-validated test for this purpose.32,33,36,42–44 Given that a majority
of this cohort was obese and that peak GH levels are negatively
correlated with BMI for all types of GH stimulation testing, including
glucagon, GHRH/arginine, and the insulin tolerance tests, it was
necessary to use a BMI-adjusted definition for GHD with a control
cohort of overweight subjects.27,34–36 Without a BMI adjustment and
using the standard cutoff for GHD, the rate of GHD in this cohort
would have been over 40%. With this more stringent and appropriate
criteria for GHD, the rate of GHD was 19.1%. Because gonadotropin
and thyrotropin-releasing hormones are no longer available com-
mercially in the United States, pituitary stimulation tests using these
hormones cannot be performed and is generally not necessary for the
clinical diagnosis of central hypogonadism or hypothyroidism.
Previous studies on postconcussive hypopituitarism
Previous studies indicate that the somatotroph and gonadotroph
axes are the most vulnerable to the primary and secondary insults of
moderate and sTBI, with deficiency rates ranging from 8% to 38%
and 0% to 29%, respectively.7–15,45,46 In contrast, corticotroph,
thyrotroph, and posterior pituitary deficiencies are less common,
with rates averaging 8%, 5%, and 2% respectively.7–15,45,46 In the
present study of mTBI subjects who sustained repetitive head im-
pact with a median of 5 concussions in their football career, a
similar pattern of hormonal deficiency was observed involving the
somatotroph and gonadotroph axes with sparing of corticotroph,
thyrotroph, and posterior pituitary function. GHD remained the
most common HD in our cohort, despite adjustment for BMI for the
diagnostic cut point for GHD. Relatively few studies have ad-
dressed the association between sports-related mTBI and hypopi-
tuitarism.47 Small case series in boxing and kickboxing have shown
a high rate of GHD, and one case report highlighted the association
between repeat concussion in an adolescent athlete and subsequent
anterior hypopituitarism.15,19,21–23,48
Quality of life, erectile dysfunction, metabolic
syndrome, and obesity
In this study, not surprisingly, men with low testosterone had
lower erectile and orgasmic scores, compared to eugonadal men,
based upon the IIEF. Hormonally deficient subjects with either
GHD or low testosterone also had lower average IIEF scores than
those without HD. Whereas there was only a trend toward lower
SF-36 MCS in the hormonally deficient group, the overall cohort
reported a poor QoL, with over 90% having an SF-36 MCS of < 49.
These findings are consistent with previous reports of TBI patients
Table 4. SF-36 and Erectile Function Scores





(n = 16) p value
QOL: SF-36 MCS,
mean – SD
37.4 – 9.6 32.9 – 10.5 0.113
QOL: SF-36 PCS,
mean – SD






55.2 – 16.8 42.8 – 20.0 0.016
QOL, quality of life; SF-36, the Short Form 36 quality-of-life
assessment; MCS, Mental Component Score; SD, standard deviation;
PCS, Physical Component Summary; IIEF, the International Index of
Erectile Function.
Table 5. Potential Demographic and Professional






Age, mean – SD) 47.1 – 10.7 years 48.1 – 8.4 years
Years in NFL (median, IQR) 5 (3–8.5) 4 (1–6)
Years in NFL (mean – SD;
p = 0.045)
6.1 – 4.0 3.9 – 2.8
NFL games played
(median, IQR)
64 (22.5–107.5) 48 (2–70)
NFL concussions
(median, IQR)
3 (2–5) 2.5 (1.0–6.5)
All concussions
(median, IQR)a




aIncludes NFL, collegiate, and high school concussions.
bHigh-frequency impact positions include offensive line, defensive line,
linebacker, and special teams, according to Guskiewicz and colleagues.33
SD, standard deviation; NFL, National Football League; IQR,
interquartile range.
HYPOPITUITARISM IN RETIRED NFL PLAYERS 1167
with GHD and/or low testosterone. Both GHD and hypogonadism
have been associated with poor QoL.49–60
In addition to poor QoL, both GHD and hypogonadism can
contribute to decreased lean body mass, increased fat mass (in
particular, visceral fat), and poor exercise capacity that further
contribute to poor QoL, obesity, and MetS, increasing cardiovas-
cular disease (CVD) risk.51,54,57,61–70 Studies have shown that
MetS is associated with, and predicts the development of, low se-
rum testosterone levels in men.62,64,65,71 Five of 6 subjects with
hypogonadism had MetS and obesity. However, whereas obesity
was present in 65% of subjects and MetS in 49% of subjects, these
rates were statistically not different in subjects with and without
any hormonal deficiency. Thus, it is likely that other factors, such as
football-related orthopedic injuries, diet, and exercise habits, and
other medical comorbidities, contributed to subjects’ development
of obesity and MetS and CVD risk.
Etiology of hypopituitarism in mild traumatic brain injury
No correlation was found between the development of hormonal
dysfunction and the number of self-reported football-related con-
cussions sustained in the NFL or throughout their football career
from high school through the NFL. This finding was somewhat
surprising, given that earlier studies by our group have shown a
strong association between recurrent concussion and lifetime de-
pression and mild cognitive impairment. In two studies by Guski-
weicz and colleagues, they reported that retired players reporting 3
or more concussions (24.4%) were 3 times more likely to be di-
agnosed with depression and 5 times more likely to be diagnosed
with mild cognitive impairment than those who had not sustained
NFL concussions.5,6,25 In a follow-up study by Kerr and colleagues,
of 1044 members of the NFL Retired Players Association, 10%
reported being clinically diagnosed with depression, which ranged
from 3% in those with no concussions to 27% for those with 10 or
more concussions.72 Notably, in the present study, other measures
of head impact exposure, including years in the NFL, games
played, and position played, similarly did not predict development
of subsequent hormonal dysfunction. This lack of correlation be-
tween concussion history and hypopituitarism raises the issue of
what other factors might lead to eventual hormonal deficiencies in
these retired athletes. It is possible that multiple subconcussive
impacts sustained over a long career could lead to eventual hor-
monal dysfunction.73 Other non-football-related etiologies of GHD
and hypogonadism, such as age-related and obesity-associated
decline in serum testosterone and GH, may also be important fac-
tors to consider in this population of retired athletes. The ac-
knowledged use of performance-enhancing steroids, which was
documented in a minority of subjects, was not associated with any
hormonal dysfunction. Notably, the overall rate of admitted steroid
use in this cohort (13%) was similar to the 9% rate from a larger
cohort of over 2552 retirees in an earlier study by our group.24
Study limitations and future investigations
Although the current study is the first to evaluate hormonal
dysfunction in retired NFL players, it is not without some limita-
tions. First, a larger sample size would be beneficial to determine
whether these preliminary findings are valid in a larger population
of NFL retirees and may have allowed for comparison of subjects
with different types of hormonal dysfunction. Second, only 17% of
the retirees invited to take part in the study ultimately did partici-
pate, which introduces a selection bias. Third, it would be important
to determine the rate of hypopituitarism in a cohort of NFL retirees
with a good QoL based on their SF-36 scores or similar validated
QoL measures. Fourth, a more comprehensive assessment of con-
cussion history, including severity and interval between concus-
sions, may have provided new insights regarding the relationship
between mTBI and hormonal dysfunction.25 Fifth, additional in-
formation regarding subjects’ football-related orthopedic injuries
and medical comorbidities as well as diet and exercise regimens
may have helped to unravel the potential relationships between
concussion, obesity, and QoL. Sixth, despite our attempts to de-
termine whether retirees used performance-enhancing (anabolic)
steroids during their NFL career, we cannot be certain that some
subjects did, in fact, use such substances and failed to admit this
fact. In a subset of subjects, it is also possible that steroid use had a
lasting effect on pituitary function, especially with a prolonged
duration and high-dose use. However, in the 3 subjects with HD
who did acknowledge such use, the duration of 1 year or less, and at
least a decade interval between such use and their hormonal testing,
would suggest that steroid use was not an important factor in their
development of HD. Finally, in future studies, brain and pituitary
magnetic resonance imagings may be helpful in documenting the
long-term structural effect of repetitive sports-related concussions
on both brain and hypothalamic-pituitary function.
Clinical implications
Retired professional football players have a relatively high rate
of poor QoL, depression, and other neurocognitive deficits, com-
pared to the general population.5,6,72 Though the cause of hormonal
dysfunction in this selected subset of NFL retirees remains some-
what unclear, the finding of GHD in almost 20% of retirees and
hypogonadism in almost 10% of retirees is significant. Given the
well-documented clinical manifestations of untreated GHD and
low testosterone, these hormonal deficits may be contributing
factors to poor QoL, erectile dysfunction, obesity, and MetS, as
well as to cognitive decline and depression, in these retired athletes.
Although preliminary, these findings have implications for all ac-
tive and retired athletes exposed to repetitive head impact and
sports-related concussion. For such individuals who exhibit
symptoms and signs of hypopituitarism, pituitary hormonal testing
should be considered. Specific complaints and signs typically as-
sociated with GHD and hypogonadism, such as weight gain, de-
creased exercise capacity, fatigue, low libido, depression, and
cognitive decline, should trigger a pituitary hormonal evaluation.
Documented GHD, low testosterone, or other deficiencies, such as
hypothyroidism or adrenal insufficiency, should be appropriately
treated in consultation with an endocrinologist. Specifically, be-
cause it relates to the findings of GHD and hypogonadism in this
study, GH replacement is known to improve QoL in patients with
adult-onset GHD and helps reduce fat mass and improve exercise
capacity.51,52,54,55,74–80 The benefits of testosterone therapy for
men are clear and considered standard practice.50,57,81 In addition,
the high prevalence of MetS in retired football players is important
because lifestyle changes may reverse some of these findings and
improve the cardiovascular and metabolic disease risks that are
associated with MetS. Lifestyle changes to reduce weight with
appropriate hormonal supplement in these former athletes may
improve not only QoL, but also decrease disease risks.
Conclusions
In this cohort of retired professional football players, using a
stringent BMI-adjusted definition of GHD, chronic hypopituitarism
was present in 23.5% of subjects and MetS in 50%. Over 50% of
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our subjects suffered 3 or more concussions during their NFL ca-
reer. As observed in other types of TBI, the somatotroph and go-
nadotroph axes appear to be the most vulnerable to sports-related
concussion and repetitive head impact. Though a causative link
between repetitive mTBI and hormonal dysfunction has not been
proven in this study, these hormonal deficiencies and metabolic
disturbances may be important factors in the overall poor QoL and
general health of many retired football players. Further study of
pituitary function involving a larger number of subjects is war-
ranted in athletes sustaining repetitive head impact.
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